To investigate the impact of targeting EZH2 methyltransferase activity on the development of IBD, we first treated healthy C57BL/6 mice with GSK343 and GSK126 (both compounds compete with S-adenosyl-methionine for binding to EZH2, thereby inhibiting histone methyltransferase activity without affecting EZH2 protein expression). The gene discussed is PRDM9; the disease is inflammatory bowel disease.